DAPT Recommendations for NSTEMI Patients After CABG

Core Recommendation

• The European Society of Cardiology recommends resuming P2Y12 inhibitor therapy postoperatively to complete a full 12 months of DAPT after the NSTEMI event, regardless of when CABG occurred during that timeframe (Class I, Level C-LD recommendation) 1, 2, 3
• The American College of Cardiology recommends aspirin 75-100 mg daily should be continued throughout the perioperative period and indefinitely thereafter (Class I, Level B-NR recommendation) 4, 1, 2

Timing of P2Y12 Inhibitor Resumption

• The European Society of Cardiology recommends resuming P2Y12 inhibitor as soon as it is deemed safe postoperatively, typically within 24-48 hours when hemostasis is secured and bleeding risk is controlled 4
• The Heart Team should estimate individual bleeding and ischemic risks to guide the timing of resumption (Class I, Level C recommendation) 4

Choice of P2Y12 Inhibitor

• The American College of Cardiology suggests ticagrelor may be preferred over clopidogrel in ACS patients, as post-hoc analysis from the PLATO study demonstrated significant reduction in cardiovascular mortality compared to clopidogrel in patients who underwent CABG 1, 2, 5
• Prasugrel showed significantly lower 30-day mortality than clopidogrel in CABG patients from TRITON-TIMI 38, but with more postoperative blood loss 1, 2, 5

Duration Algorithm

• For NSTEMI patients undergoing CABG, the European Society of Cardiology recommends aspirin 75-100 mg daily + P2Y12 inhibitor (resume postoperatively and continue to complete 12 months from ACS event) 4, 1, 2

Bleeding Risk Modifications

• The European Society of Cardiology recommends considering discontinuation of P2Y12 inhibitor after 6 months in CABG patients with prior MI and high bleeding risk (PRECISE-DAPT ≥25) (Class IIa, Level C recommendation) 4
• Patients with increased bleeding risk may favor shorter-than-recommended DAPT duration, but this must be balanced against ischemic risk in the ACS setting 2

Critical Evidence Supporting This Approach

• The CURE study demonstrated reduction in ischemic events in ACS patients treated with aspirin plus clopidogrel who underwent CABG 1, 2, 5, 6
• Danish registry data showed significantly fewer deaths during mean follow-up in CABG patients treated with aspirin plus clopidogrel versus aspirin alone after ACS 1, 2, 5, 6

Common Pitfalls to Avoid

• The European Society of Cardiology recommends not discontinuing P2Y12 inhibitor prematurely after CABG in NSTEMI patients—the 12-month duration is calculated from the ACS event, not from the surgery date 4, 1, 2
• The American College of Cardiology recommends not failing to resume P2Y12 inhibitor postoperatively—this is a Class I recommendation and critical for reducing mortality and cardiovascular events in ACS patients 4, 1, 2

Antiplatelet Regimen After CABG

Standard Aspirin Monotherapy

• The American College of Cardiology and European Heart Journal recommend low-dose aspirin (75-100 mg daily) to be started within 6-24 hours after CABG once hemostasis is secured and continued indefinitely 7, 8, 9
• Aspirin improves saphenous vein graft patency, particularly during the first postoperative year, and reduces major adverse cardiac events (MACE) and mortality 7, 10
• For patients on aspirin preoperatively, it should be continued through the perioperative period at low daily doses 8

Dual Antiplatelet Therapy (DAPT) After CABG

• The American College of Cardiology recommends resuming P2Y12 inhibitor therapy postoperatively to complete 12 months of DAPT after an acute coronary syndrome (ACS) event 7, 11, 8
• Patients with prior coronary stenting should resume P2Y12 inhibitor postoperatively to complete the recommended duration of DAPT for the stent type (minimum 1 month for bare metal stents, at least 6 months for drug-eluting stents) 7, 11
• DAPT with clopidogrel initiated early postoperatively for 12 months may be reasonable to improve vein graft patency in patients with stable ischemic heart disease (SIHD) without ACS 7, 11, 12

Choice of P2Y12 Inhibitor

• Clopidogrel 75 mg daily is the most studied agent in CABG patients and is appropriate for most situations 7, 8
• Ticagrelor may be preferred over clopidogrel in ACS patients, as it demonstrated significant reduction in cardiovascular mortality compared to clopidogrel 7

Timing of P2Y12 Inhibitor Resumption

• Resume P2Y12 inhibitor therapy as soon as it is deemed safe postoperatively, typically within 24-48 hours when bleeding risk is controlled 8

Bleeding Risk Management

• Consider adding a proton pump inhibitor (PPI) in patients at increased risk of gastrointestinal bleeding (elderly, history of GI bleeding, chronic NSAID use, combination antithrombotic therapy) 9, 10
• PPIs are effective in reducing GI bleeding risk with antithrombotic therapy 9

Preoperative Management

• For elective CABG, discontinue P2Y12 inhibitors before surgery: prasugrel stop ≥7 days before, clopidogrel stop ≥5 days before, ticagrelor stop ≥3 days before 8
• Continue aspirin through the perioperative period 8

Duration Summary Algorithm

• All CABG patients should receive aspirin 75-100 mg daily indefinitely 7, 8, 9
• Add P2Y12 inhibitor for 12 months if there is a recent ACS or prior coronary stent 7, 11, 8

Dual Antiplatelet Therapy After CABG to Improve Graft Patency

Clinical Context Determines DAPT Strategy

• The American College of Cardiology recommends resuming P2Y12 inhibitor therapy postoperatively and continuing for 12 months total from the ACS event for patients with acute coronary syndrome (ACS) undergoing CABG, with a Class I, Level C-LD recommendation 13
• For patients with stable ischemic heart disease (SIHD), DAPT with clopidogrel for 12 months may be reasonable to improve vein graft patency, though the evidence is weaker and bleeding risk must be carefully weighed, with a Class IIb, Level B-NR recommendation 14, 15
• The American College of Cardiology recommends aspirin 75-100 mg daily should be continued throughout the perioperative period and indefinitely for patients undergoing CABG 13, 15

Evidence for Graft Patency Benefit

• A meta-analysis of 5 RCTs and 6 observational studies demonstrated that DAPT was associated with reduced vein graft occlusion and 30-day mortality compared to aspirin monotherapy 16, 13
• The CURE study demonstrated reduction in ischemic events in ACS patients treated with aspirin plus clopidogrel who underwent CABG, with benefit observed primarily before the procedure 16
• Danish registry data showed significantly fewer deaths during mean follow-up in CABG patients treated with aspirin plus clopidogrel versus aspirin alone after ACS 16

Choice of P2Y12 Inhibitor

• Ticagrelor may be preferred over clopidogrel in ACS patients based on post-hoc analysis from the PLATO study showing significant reduction in cardiovascular mortality compared to clopidogrel in CABG patients 16, 15
• Prasugrel showed significantly lower 30-day mortality than clopidogrel in CABG patients from TRITON-TIMI 38, but with more postoperative blood loss 16, 15

Bleeding Risk Management

• Major bleeding after surgery is more frequent with DAPT compared to aspirin monotherapy 16, 13
• The American College of Cardiology recommends considering discontinuation of P2Y12 inhibitor after 6 months in CABG patients with prior MI and high bleeding risk (PRECISE-DAPT ≥25) 14, 15

Antiplatelet Therapy Recommendations After Coronary Artery Bypass Grafting

Aspirin Monotherapy (Standard for All CABG Patients)

• Initiate aspirin within 6 hours after surgery once hemostasis is secured and continue indefinitely – Class I, strong recommendation (American College of Cardiology/American Heart Association). 17
• Dose aspirin 75–100 mg daily (up to 325 mg allowed); prefer low‑dose 81 mg for long‑term maintenance – Class I, strong recommendation. [18][19]17

Dual Antiplatelet Therapy (DAPT) for Patients With Recent Acute Coronary Syndrome (ACS)

• Resume a P2Y12 inhibitor post‑operatively and continue DAPT to complete a total of 12 months from the index ACS event (not from the CABG date) – Class I, strong recommendation. [19][20]
• Start the P2Y12 inhibitor 24–48 hours after surgery once bleeding risk is acceptable – Class I, strong recommendation. [19][20]

DAPT for Stable Ischemic Heart Disease (SIHD) Without Recent ACS

• Consider clopidogrel 75 mg daily for 12 months in addition to aspirin to improve vein‑graft patency when bleeding risk is low – Class IIb, weak recommendation. 20

Bleeding‑Risk‑Guided Modifications of DAPT

• If the PRECISE‑DAPT score ≥ 25 (high bleeding risk) in a stable patient without recent ACS, discontinue the P2Y12 inhibitor after 6 months rather than 12 months – Class IIb, weak recommendation. 20
• High‑bleeding‑risk factors include:
  
  • Concurrent oral anticoagulation therapy – Class IIb. 19
  • Prior major bleeding while on DAPT – Class IIb. 20
  • Planned major intracranial surgery – Class IIb. 20
  • Underlying coagulopathy – Class IIb. [19][20]18
• Add a proton‑pump inhibitor for all patients on DAPT who have increased gastrointestinal bleeding risk (e.g., elderly, prior GI bleed, chronic NSAID use) – Class IIa, moderate recommendation. 21

Pre‑operative Management of Antiplatelet Agents

• Elective CABG – discontinue clopidogrel and ticagrelor at least 5 days before surgery; discontinue prasugrel at least 7 days before surgery; continue aspirin throughout the peri‑operative period. – Class I, strong recommendation. 17
• Urgent CABG – when feasible, stop clopidogrel and ticagrelor at least 24 hours before surgery. – Class I, strong recommendation. 17

Summary Algorithm (Key Points)

• All CABG patients: aspirin 75–100 mg daily started within 6 hours post‑op and continued indefinitely. [18][17]
• Add a P2Y12 inhibitor when:
  
  • Recent ACS (≤12 months) – resume post‑op and complete 12 months from ACS event. [19][20]
  • Stable SIHD without recent ACS – consider clopidogrel for 12 months if bleeding risk is low (Class IIb). 20
• Modify DAPT duration if high bleeding risk develops – stop P2Y12 after 6 months in stable patients (Class IIb). 20
• Never shorten DAPT in ACS patients unless life‑threatening bleeding occurs. 19